Drug Profile, Screen with Reflex to Quantitation
Also known as: PAIN RFX U
Use
This test is primarily used in the context of compliance and/or abuse monitoring, typically in pain management scenarios. It provides a general screening for the presence of multiple drugs and their metabolites in urine. The test is useful for evaluating medication adherence or misuse, and it includes a reflex to quantitative confirmation if a drug is detected initially.
Special Instructions
For medical purposes only; not valid for forensic use. Specimens must be random urine collected without additives or preservatives and transferred into ARUP Standard Transport Tubes.
Limitations
This test does not distinguish between the delta-8 and delta-9 forms of THC or their metabolites. Presumptive negative results might indicate non-compliance, inappropriate timing relative to drug administration, poor drug absorption, diluted or adulterated urine, or testing limitations. The concentration at which detection occurs varies depending on the drug class.
New York Approved
Methodology
Immunoassay (EMIT)
Biomarkers
LOINC Codes
- 2161-8
- 19261-7
- 19359-9
- 19659-2
- 19292-2
- 19270-8
- 14316-4
- 19429-0
- 19550-3
- 19295-5
- 58430-0
- 58375-7
- 54247-2
- 93494-3
- 21142-5
- 11235-9
- 3746-5
- 72485-6
- 19710-3
- 94104-7
Result Turnaround Time
1-8 days
Related Documents
For more information, please review the documents below
Specimen
Urine
Volume
4 mL each into two tubes
Minimum Volume
2 mL each
Container
ARUP Standard Transport Tubes
Collection Instructions
Transfer urine into the transport tubes; no preservatives should be added.
Causes for Rejection
Specimens exposed to multiple freeze/thaw cycles, Pharmaceutical preparation.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 1 week |
| Refrigerated | 1 month |
| Frozen | 1 month |